Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 351

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 351
---
 to interpret their results, and receive a health plan with recommendations to target the prevention of certain health issues and achieve health objectives. 178 On January 9, 2024, OmnigenicsAI was incorporated in the Cayman Islands. On February 26, 2024, the Parent entered into a contribution agreement with OmnigenicsAI, pursuant to which Parent contributed to OmnigenicsAI all of the issued and outstanding shares in Heritas Argentina, making Heritas Argentina a wholly owned subsidiary of OmnigenicsAI. OmnigenicsAI issued 30,000,000 Company Shares to Parent in connection with the Heritas Argentina contribution. In 2025, after selling Rewell for two and a half years through a direct -to-consumermodel, we decided to transition the marketing of Rewell to a business -to-business-to-consumerbusiness model. This decision was driven by the rising costs associated with direct -to-consumersales and the advancement of AI models, which we plan to utilize to enable more efficient scaling of Rewell. We believe that marketing Rewell through business -to-business-to-consumerchannels will create synergies with our goal to develop strategic partnerships therefore increasing Rewell’s market penetration at a lower cost for us. As a result of this, we streamlined operations by consolidating Rewell and Heritas Diagnostics under a unified structure, and reduced the number of employees from49, as of June30, 2024, to 25 employees as of the date of the registration statement of which this prospectus is part. Our Operating Segments We operate across two segments within our corporate structure, dedicated to providing precise and secure biological data to empower individuals to make informed health choices. Our business units operate at the forefront of scientific development, genetic testing and will be integrated with AI -driventechnology, designed to address the entire spectrum of healthcare needs, spanning prevention diagnosis and prognosis, integrating a wide range of clinical, biological, and lifestyle data. The services within these segments have been developed based on our experience in Latin America, allowing us to adapt our tests and results based on local language and specific needs. With a focus on precision, privacy, and accessibility, OmnigenicsAI is committed to empowering individuals and healthcare providers with the tools necessary for proactive health management through the following categories with its current brands: • Rewell: personalized wellness and preventative health solutions that integrate genetic, microbiome and lifestyle data, with nutrigenetic guidance tailored to each user. Through our digital platform, users access DNA